MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jjco/hyag174

Медицинская библиотека · Japanese journal of clinical oncology · 2026

Primary feasibility analysis of neoadjuvant chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer: the NAVAL phase II study.

Tsubokawa Norifumi, Tsutani Yasuhiro, Miyata Yoshihiro, Suzuki Kenji, Takamochi Kazuya, Tanaka Fumihiro, Ito Hiroyuki, Yamashita Yoshinori, Oda Makoto, Mimae Takahiro, Okada Morihito

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

Bevacizumab (Bev) improves the response and survival rates in patients with advanced non-small cell lung cancer (NSCLC). This phase II trial aimed to assess the feasibility of adding Bev to preoperative chemotherapy in resectable non-squamous NSCLC.

METHODS

Patients with clinical stage II/IIIA non-squamous NSCLC (n = 30) received three cycles of cisplatin (Cis), pemetrexed (Pem), and Bev, followed by surgical resection. The primary endpoint was the complete resection rate (CRR), defined as the proportion of all eligible enrolled patients who ultimately underwent complete (R0) resection. The sample size was set at 30 patients. Treatment was considered feasible if the CRR exceeded the predefined acceptable threshold of 65%.

RESULTS

Radiological tumour reduction was observed in 29 of 30 patients (97%). Twenty-eight patients (93%) completed all three cycles of chemotherapy, and 25 patients (83%) underwent surgery. Five patients discontinued treatment due to adverse events (n = 3), disease progression (n = 1), or patient refusal (n = 1). Complete resection was achieved in all resected patients, yielding an 83% CRR (two-sided 80% confidence interval, 71.3%-91.7%). The objective response rate was 37%, and pathological complete response of the primary tumour was achieved in 3 patients (12%). Grade 3 toxicities included neutropenia (7%), nausea (7%), hypertension (23%), and pulmonary embolism (3%). No grade 4/5 adverse events occurred within 28 days, and no treatment-related deaths occurred within 84 days.

CONCLUSIONS

Preoperative Cis, Pem, and Bev for clinical stage II/IIIA non-squamous NSCLC met the predefined feasibility criterion, with acceptable safety in this selected population. These findings provide historical insights supporting perioperative anti-vascular endothelial growth factor-based systemic intensification.

Для цитирования: Tsubokawa Norifumi, Tsutani Yasuhiro, Miyata Yoshihiro, Suzuki Kenji, Takamochi Kazuya, Tanaka Fumihiro, Ito Hiroyuki, Yamashita Yoshinori, Oda Makoto, Mimae Takahiro, Okada Morihito. Primary feasibility analysis of neoadjuvant chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer: the NAVAL phase II study.. Japanese journal of clinical oncology. 2026. DOI: 10.1093/jjco/hyag174.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.